Intragenic suppression of trafficking-defective KCNH2 channels associated with long QT syndrome

Area of Science:

• Molecular biology
• Genetics
• Cardiology

Background:

• Mutations in the KCNH2 gene cause long QT syndrome (LQT2), a condition affecting heart rhythm.
• Class 2 LQT2 mutations impair KCNH2 channel protein trafficking, reducing its expression at the cell surface.
• Certain drugs can improve trafficking of these defective channels by binding to the pore-S6 domain.

Purpose of the Study:

• To investigate if specific amino acid substitutions within the KCNH2 drug binding domain can intrinsically correct trafficking defects caused by LQT2 mutations.
• To test the hypothesis that altering residue Y652 can compensate for protein folding abnormalities in class 2 LQT2 mutations.

Main Methods:

• Utilized intragenic suppression strategy to introduce targeted amino acid substitutions.
• Introduced Y652C and Y652S substitutions into the KCNH2 gene.
• Assessed the impact of these substitutions on Golgi processing and suppression of LQT2 phenotypes (G601S, V612L, F640V, N470D, F805C).

Main Results:

• The Y652C substitution demonstrated significant intragenic suppression of the G601S LQT2 mutation, enhancing Golgi processing of the channel protein.
• Y652S also showed partial intragenic suppression of the G601S phenotype.
• Y652C suppressed the V612L and F640V LQT2 mutations but did not affect N470D or F805C mutations.

Conclusions:

• A single amino acid substitution at residue Y652 within the KCNH2 drug binding domain can intrinsically suppress the functional defects of several class 2 LQT2 mutations.
• This finding provides the first evidence for intragenic suppression of LQT2 mutations via targeted modification of the channel's drug binding site.
• Suggests potential for developing novel therapeutic strategies for LQT2 by directly correcting channel protein trafficking.